Date: April 22, 2017 @ 1:30 pm – @ 4:00 pm
Location: Genentech Building 31, 310 DNA Way, South San Francisco CA, 94080


If any company is interested in sponsoring, please contact 

Please register online. Online registration is free for CABS members and $10 for non-members. You can become a CABS member and register online free. Onsite registration is $10.

1:30-2:00PM check-in, onsite registration and networking



1. Benjamin Haley, PhD, Scientist, Genentech, Inc.

During his graduate studies, Ben unraveled several biochemical mechanisms that characterize the RNAi pathway. After receiving his PhD, he went to Mike Levine’s lab at UC Berkeley as an American Cancer Society Postdoctoral Fellow. There, he developed an enhanced Drosophila RNAi system for in vivo applications, further refined the in vivo specificity of RNAi, and identified novel aspects of small RNA biogenesis and mRNA structure/expression using a host of model organisms. Following his postdoc, Ben joined Genentech, Inc. where he currently serves as a point person for applied functional genetics. His lab is focused on developing technologies to better model human disease and therapeutic intervention using cell-based experiments.

Talk title: CRISPR platform overview and functional genomic screening for drug target discovery and validation

2. Dr. Ruby Chen-Tsai 陈雁如, PhD, Co-founder and Chief Scientific Officer, Applied StemCell, Inc.

Dr. Chen-Tsai received her PhD from Cornell University and did her post-doc research at Stanford University. She has been working with stem cells and genetic cell and animal models for 25 years. Prior to joining Applied StemCell, Dr. Chen-Tsai worked at Stanford University for 16 years as the Director of Transgenic Research Center and Associate Director of the Stanford Cancer Institute, overseeing nine research technology labs. Dr. Chen-Tsai is a co-inventor of the TARGATT™ integrase technology and a related “DICE” technology for site-specific gene insertion. Her current research focuses on stem cell based gene therapy using most advanced genome editing technologies including CRISPR/Cas9 and Applied StemCell, Inc.’s proprietary TARGATTTM technologies. Dr. Chen-Tsai is an author of many scientific papers published in Science, PNAS, Genetics, Cell Stem Cell, and etc. and holder of several patents. She is an awardee of several NIH grants, California Institute of Regenerative Medicine grant, and Invest Northern Ireland government grant.

Title: New CRISPR technologies and complex genome engineering for discovery and gene therapy.

Online Registration_CABS members – $0 (USD)
Online Registration_Non-member – $10 (USD)